Apotex Corp., a major generic drugmaker, has paid Bristol-Myers Squibb Co. and Sanofi SA more than $442 million to end a decade-long patent infringement lawsuit over blockbuster blood thinner Plavix, the world’s second-best-selling drug. Apotex Corp., which is Canada’s biggest drugmaker, paid the two brand-name drugmakers $442.2 million in damages for selling a generic version of Plavix in 2006.
Apotex launched its copycat version while it was still in litigation with Bristol and Sanofi, partners who jointly market Plavix. Apotex contended in the lawsuit that key patents on Plavix were invalid. Apotex was doing what is referred to as an “at-risk launch” of its generic version of Plavix. But a federal judge later ruled in the lawsuit that the Plavix patent was valid. That ruling led to the payment by Apotex of damages to the brand manufacturers, which will end the litigation.
Source: CBS News
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.